Alpha Cognition Reports Strong ZUNVEYL Sales Growth but Deepens Losses

Event summary

  • ZUNVEYL generated $6.8M in net product revenue in 2025, with Q4 sales up 62% QoQ.
  • Prescriber base grew 50% in Q4, with cumulative homes prescribing up 26%.
  • Operating loss widened to $22.7M from $12.0M in 2024 due to commercial investment.
  • Cash position stands at $66M, providing ~2-year runway post-$40M capital raise.
  • Secured second national PBM contract, covering two of four major long-term care PBMs.

The big picture

Alpha Cognition's strong ZUNVEYL sales growth reflects the unmet need for new Alzheimer's treatments, but its widening losses highlight the challenges of scaling commercial operations. The company's focus on long-term care adoption and payer partnerships positions it in a competitive but growing market for neurodegenerative therapies. With $66M in cash and a two-year runway, execution on commercial expansion and cost management will be critical.

What we're watching

Commercial Momentum
Whether Alpha Cognition can sustain ZUNVEYL's 62% QoQ sales growth amid rising competition in Alzheimer's treatments.
Payer Expansion
The pace at which Alpha Cognition secures additional PBM contracts to drive broader payer coverage.
Path to Profitability
How the company balances aggressive commercial investment with its goal of operational profitability by 2027.